Hemophilia A secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(One intermediate revision by one other user not shown)
Line 4: Line 4:


==Overview==
==Overview==
[[Secondary prevention]] for [[Hemophilia A]] is aimed at preventing spontaneous or excessive bleeds in patients who are high risk, and relies on the use of recombinant clotting [[factor VIII]] to prevent bleeding episodes.
[[Secondary prevention]] for [[Hemophilia A|Hemophilia]] is aimed at preventing spontaneous or excessive bleeds in patients who are high risk, and relies on the use of recombinant clotting [[factor VIII]]/ IX to prevent bleeding episodes.


==Secondary Prevention==
==Secondary Prevention==
Secondary preventive measures to avoid Hemophilia A include the following:
Secondary preventive measures to avoid Hemophilia A and B include the following:
*Patients should be counseled on safe practices and routine accident prevention
*Patients should be counseled on safe practices and routine accident prevention.
*Patients with moderate-to-severe hemophilia may be managed with prophylactic transfusions of recombinant clotting factor VIII in order to prevent bleeding episodes<ref name="pmid22551339">{{cite journal| author=Franchini M, Mannucci PM| title=Past, present and future of hemophilia: a narrative review. | journal=Orphanet J Rare Dis | year= 2012 | volume= 7 | issue=  | pages= 24 | pmid=22551339 | doi=10.1186/1750-1172-7-24 | pmc=3502605 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22551339  }} </ref> The goal of [[prophylaxis]] is usually to keep clotting factor levels at 1 percent or greater at all times.<ref> Prophylaxis: Administration and dosing schedules – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-administration-and-dosing-schedules. Accessed on Sept 20, 2016 </ref>
*Patients with moderate-to-severe hemophilia may be managed with prophylactic transfusions of recombinant clotting factor VIII/ IX in order to prevent bleeding episodes.<ref name="pmid22551339">{{cite journal| author=Franchini M, Mannucci PM| title=Past, present and future of hemophilia: a narrative review. | journal=Orphanet J Rare Dis | year= 2012 | volume= 7 | issue=  | pages= 24 | pmid=22551339 | doi=10.1186/1750-1172-7-24 | pmc=3502605 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22551339  }} </ref> The goal of [[prophylaxis]] is usually to keep clotting factor levels at 1 percent or greater at all times.<ref>Prophylaxis: Administration and dosing schedules – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-administration-and-dosing-schedules. Accessed on Sept 20, 2016 </ref>
*Routine prophylactic transfusions are not recommended for patients with mild hemophilia
*Routine prophylactic transfusions are not recommended for patients with mild hemophilia.


==References==
==References==

Latest revision as of 16:14, 16 July 2018

Hemophilia A Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemophilia A from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemophilia A secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemophilia A secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemophilia A secondary prevention

CDC on Hemophilia A secondary prevention

Hemophilia A secondary prevention in the news

Blogs on Hemophilia A secondary prevention

Directions to Hospitals Treating Hemophilia A

Risk calculators and risk factors for Hemophilia A secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahd Yunus, M.D. [2]

Overview

Secondary prevention for Hemophilia is aimed at preventing spontaneous or excessive bleeds in patients who are high risk, and relies on the use of recombinant clotting factor VIII/ IX to prevent bleeding episodes.

Secondary Prevention

Secondary preventive measures to avoid Hemophilia A and B include the following:

  • Patients should be counseled on safe practices and routine accident prevention.
  • Patients with moderate-to-severe hemophilia may be managed with prophylactic transfusions of recombinant clotting factor VIII/ IX in order to prevent bleeding episodes.[1] The goal of prophylaxis is usually to keep clotting factor levels at 1 percent or greater at all times.[2]
  • Routine prophylactic transfusions are not recommended for patients with mild hemophilia.

References

  1. Franchini M, Mannucci PM (2012). "Past, present and future of hemophilia: a narrative review". Orphanet J Rare Dis. 7: 24. doi:10.1186/1750-1172-7-24. PMC 3502605. PMID 22551339.
  2. Prophylaxis: Administration and dosing schedules – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-administration-and-dosing-schedules. Accessed on Sept 20, 2016

Template:WH Template:WS